Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279845 | 0.82 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2KDM4ENPC1KMT2A | |
| SCHEMBL4272042 | 0.81 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2KDM4ENPC1KMT2A | |
| SCHEMBL4279396 | 0.78 | NPY2R (0.43) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL29944048 | 0.78 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2KDM4ENPC1KMT2A | |
| SCHEMBL4276349 | 0.75 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL4276109 | 0.74 | NPC1 (0.46) | ALDH1A1SMN1; SMN2KDM4ENPC1KMT2A | |
| SCHEMBL13658135 | 0.73 | TP53 (0.44) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL1429623 | 0.72 | KMT2A (0.79) | ALDH1A1SMN1; SMN2KDM4ENPC1KMT2A | |
| SCHEMBL4762716 | 0.72 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL8247543 | 0.72 | MEN1 (0.58) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1C, CACNA1I | ALDH1A1 1924/4885SMN1; SMN2 2531/4885KDM4E 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.